ACADIA Pharmaceuticals Receives New Coverage from Analysts at Ned Davis Research (ACAD)
Analysts at Ned Davis Research started coverage on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) in a research report issued to clients and investors on Monday, Stock Ratings Network reports. The firm set a “neutral” rating on the stock.
A number of other firms have also recently commented on ACAD. Analysts at Roth Capital raised their price target on shares of ACADIA Pharmaceuticals from $20.00 to $23.00 in a research note to investors on Thursday, August 8th. They now have a “buy” rating on the stock. Separately, analysts at Zacks reiterated an “outperform” rating on shares of ACADIA Pharmaceuticals in a research note to investors on Wednesday, August 7th. They now have a $26.00 price target on the stock. Finally, analysts at Ladenburg Thalmann raised their price target on shares of ACADIA Pharmaceuticals from $15.00 to $24.00 in a research note to investors on Wednesday, August 7th. They now have a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company’s stock. ACADIA Pharmaceuticals has a consensus rating of “Buy” and an average target price of $23.43.
In other ACADIA Pharmaceuticals news, CFO Thomas H. Aasen sold 30,000 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $27.87, for a total transaction of $836,100.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
ACADIA Pharmaceuticals (NASDAQ:ACAD) traded down 3.04% during mid-day trading on Monday, hitting $27.895. The stock had a trading volume of 1,472,957 shares. ACADIA Pharmaceuticals has a 1-year low of $1.80 and a 1-year high of $29.73. The stock’s 50-day moving average is $23.11 and its 200-day moving average is $17.10. The company’s market cap is $2.477 billion.
ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings data on Tuesday, August 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.02. The company had revenue of $451.00 million for the quarter, compared to the consensus estimate of $0.45 million. On average, analysts predict that ACADIA Pharmaceuticals will post $-0.44 earnings per share for the current fiscal year.
ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.